Sarepta Therapeutics, Inc. insider trading

Bought

—

Sold

$123.2K

none on a 10b5-1 plan

Net

−$123.2K

Insiders

1

• Mayo Stephen

  Director

  −$123.2K

  Mar 12, 2026

  7,239 sh · $17.02

Largest purchase

+$2.5M of SRPT by Chambers Michael Andrew (Director) on Aug 16, 2024.

Largest sale

−$1.3M of SRPT by Wigzell Hans Lennart Rudolf (Director) on Dec 12, 2024.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

Pharmaceutical Preparations

Headquarters

Cambridge, MA

Incorporated in

DE

Listed on

Nasdaq

SEC Central Index Key

0000873303

Previously filed as

AVI BIOPHARMA INC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are SRPT insiders buying or selling?

Between Mar 12, 2026 and Mar 12, 2026, 1 Sarepta Therapeutics, Inc. insider made no open-market purchases and 1 sale worth $123.2K, a net sale of $123.2K.

How much SRPT stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 6 Sarepta Therapeutics, Inc. insiders made 3 open-market purchases worth $5M and 6 sales worth $3M. In the four quarters to Jun 30, 2026: no purchases and 2 sales ($417.4K). The largest purchase was Chambers Michael Andrew buying $2.5M on Aug 16, 2024. The largest sale was Wigzell Hans Lennart Rudolf selling $1.3M on Dec 12, 2024.

What was the largest recent SRPT insider trade?

Mayo Stephen (Director) sold $123.2K of SRPT stock on Mar 12, 2026 at about $17.02 a share.

When did an insider last buy SRPT shares?

No open-market purchase by a Sarepta Therapeutics, Inc. insider appears in the filings from Mar 12, 2026 to Mar 12, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Chambers Michael Andrew buying $2.5M on Aug 16, 2024.

Where does SRPT insider trading data come from?

From the Form 4 filings Sarepta Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.